The testing facilities need to be suitably resourced to be able keep pace with the new exciting tumour targets and treatments that are being discovered and shown to be promising in clinical trials, such as the recently developed tyrosine kinase inhibitors for BRAF mutations in melanoma and EML4-ALK mutations in NSCLC. This evidence concerns the gene BRAF and non-small cell lung carcinoma.